Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis.
Twenty adult patients with cystic fibrosis who were experiencing acute pulmonary exacerbations were enrolled in a randomized, controlled trial comparing oral ciprofloxacin with intravenous tobramycin plus azlocillin. Efficacy of the two treatments was compared based upon changes in clinical status, pulmonary function tests, white blood cell counts, and quantitative bacteriology of sputum. No statistically significant differences were detected in these parameters of response between the two treatment groups (p greater than 0.05). Ciprofloxacin appears to be therapeutically equivalent to intravenous antibiotics in the treatment of adult patients with cystic fibrosis who are experiencing pulmonary exacerbations associated with susceptible bacteria.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001390:Azlocillin / Q000008:administration & dosage; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy*; D011897:Random Allocation; D013810:Therapeutic Equivalency; D014031:Tobramycin / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D001390:Azlocillin; D014031:Tobramycin